UCB celebrates the Grand opening of a new facility in Shannon in
presence of H.M. King Albert II, and appeals to build on Belgian
strong innovative capacities
Shannon, Ireland, October 10, 2007 at 13:00 PM (CET) - UCB welcomed
today H.M. Albert II, King of the Belgians for the Grand Opening of a
new facility.
The new manufacturing facility will enable the production of
Fesoterodine, a new drug to combat over-active bladder (incontinence)
which has been developed by Schwarz Pharma, now part of the UCB
Group, and is licensed exclusively to Pfizer.
Construction of the facility, along with other site upgrade projects
will be completed by the end of this year and the plant will be in
operation in the first quarter of 2008.
Dr Roch Doliveux, CEO and Chairman of the Executive Committee of UCB
said: "This new facility will enable the production of an important
new drug here. With 815Mio EUR investments worldwide in R&D, in 2006
and the full integration of Schwarz Pharma, UCB is actively building
the next generation biopharma leader.
UCB today is large enough to advance an especially rich pipeline and
to launch our new products to specialists first.
The recent launches of Neupro and Xyzal in the US demonstrate the
power to execute our projects"
UCB takes advantage of the state visit of HM Albert II, King of the
Belgians to highlight the need for a common platform between Belgian
universities and innovative industries, to make Belgium a leader in
education, Research and Development.
Based on this success in Ireland but also in the USA, Dr. Roch
Doliveux calls for the increasing of public research, university
funding and improvement of education in Europe and in Belgium to
build on Belgian strong innovative capacities especially in sectors
as Biopharma, ICT and nanotechnology.
Further information
Xavier Hormaechea
Public Affairs
T +32.2.559.9763
Xavier.hormaechea@ucb-group.com
About UCB
UCB, Brussels, Belgium (www.ucb-group.com) is a global leader in the
l biopharmaceutical industry dedicated to the research, development
and commercialisation of innovative pharmaceutical and biotechnology
products in the fields of central nervous system disorders,
allergy/respiratory diseases, immune and inflammatory disorders and
oncology - UCB focuses on securing a leading position in severe
disease categories. Employing more than 10,000 people in over 40
countries, UCB achieved revenue of 3.5 billion euro in 2006 on a pro
forma basis. UCB is listed on the Euronext Brussels Exchange and owns
approx. 89% of the shares of SCHWARZ PHARMA AG. SCHWARZ PHARMA AG
(Monheim, Germany) is a member of UCB Group.
Forward looking statement
This press release contains forward-looking statements based on
current plans, estimates and beliefs of management. Such statements
are subject to risks and uncertainties that may cause actual results
to be materially different from those that may be implied by such
forward-looking statements contained in this press release. Important
factors that could result in such differences include: changes in
general economic, business and competitive conditions, effects of
future judicial decisions, changes in regulation, exchange rate
fluctuations and hiring and retention of its employees.
For the pdf-version of this press release, please click on the link
below:
